Linked Life Data

16556029

Source:http://linkedlifedata.com/resource/pubmed/id/16556029

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2006-3-24
pubmed:abstractText
Over the past decade, heat-shock protein (HSP)90 has begun to draw increasing attention as a novel anticancer target with unique features. As a molecular chaperone, HSP90 promotes the maturation and maintains the stability of a large number of conformationally labile client proteins, most of which are involved in biologic processes that are often deranged within tumor cells, such as signal transduction, cell-cycle progression and apoptosis. As a result, and in contrast to other molecular targeted therapeutics, inhibitors of HSP90 achieve their promising anticancer activity through simultaneous disruption of many oncogenic substrates within cancer cells. This review provides a brief summary of HSP90 biology and its association with cancer. It describes the discovery and development of HSP90 inhibitors as anticancer agents and their current status in the clinic. Finally, it closes with a discussion of the unique challenges confronting the further development of these agents and their prospects for the future.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1479-6694
pubmed:author
pubmed:issnType
Print
pubmed:volume
1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
529-40
pubmed:dateRevised
2006-7-3
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
HSP90: a rising star on the horizon of anticancer targets.
pubmed:affiliation
Whitehead Institute for Biomedical Research, Room 649, 9 Cambridge Center, Cambridge, MA 02142, and University of Arizona, Steele Memorial Children's Research Center, Tucson, AZ 85724, USA. cdai@wi.mit.edu
pubmed:publicationType
Journal Article, Review